Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2017 Summary Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2017, outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 11 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Ear Nose Throat Disorders which include indications Alzheimer's Disease, Hearing Disorders, Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Brain Cancer, Burkitt Lymphoma, Glioblastoma Multiforme (GBM), Leukemias, Medulloblastoma, Metastatic Breast Cancer, Soft Tissue Sarcoma, Solid Tumor and T-Cell Leukemia. Furthermore, this report also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.) - The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects - The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Gamma Secretase (EC 3.4.23.) - Overview 7 Gamma Secretase (EC 3.4.23.) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 14 Gamma Secretase (EC 3.4.23.) - Therapeutics Assessment 16 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Gamma Secretase (EC 3.4.23.) - Companies Involved in Therapeutics Development 22 Astellas Pharma Inc 22 Bristol-Myers Squibb Co 22 Critical Outcome Technologies Inc 22 Lipopharma Therapeutics SL 23 Merck & Co Inc 23 NeuroGenetic Pharmaceuticals Inc 24 Pfizer Inc 24 Stemline Therapeutics Inc 25 Takeda Pharmaceutical Co Ltd 25 Gamma Secretase (EC 3.4.23.) - Drug Profiles 27 AS-2715348 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 BMS-932481 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 BMS-986133 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 GSI-34 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 LP-226A1 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 LY-3056480 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 NGP-328 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 NGP-555 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 nirogacestat - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Peptides to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 PF-06648671 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 SL-301 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 SL-302 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecules to Inhibit Beta and Gamma Secretase for Alzheimer's Disease - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Gamma Secretase (EC 3.4.23.) - Dormant Products 49 Gamma Secretase (EC 3.4.23.) - Discontinued Products 51 Gamma Secretase (EC 3.4.23.) - Product Development Milestones 52 Featured News & Press Releases 52 Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer's Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers 52 Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer's Disease; Reports Initial Results of Phase 1a Clinical Trial 52 Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer's Disease 52 Jun 16, 2014: Prof. G.L. Nicolson and Prof. R.M. Epand join Lipopharma's SAB 53 Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease 53 Jul 21, 2009: Critical Outcome Technologies Inc. Announces the Launch of a Drug Discovery Program for Alzheimer's disease 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13 Number of Products under Investigation by Universities/Institutes, H2 2017 14 Products under Investigation by Universities/Institutes, H2 2017 15 Number of Products by Stage and Mechanism of Actions, H2 2017 17 Number of Products by Stage and Route of Administration, H2 2017 19 Number of Products by Stage and Molecule Type, H2 2017 21 Pipeline by Astellas Pharma Inc, H2 2017 22 Pipeline by Bristol-Myers Squibb Co, H2 2017 22 Pipeline by Critical Outcome Technologies Inc, H2 2017 23 Pipeline by Lipopharma Therapeutics SL, H2 2017 23 Pipeline by Merck & Co Inc, H2 2017 24 Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2017 24 Pipeline by Pfizer Inc, H2 2017 25 Pipeline by Stemline Therapeutics Inc, H2 2017 25 Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 26 Dormant Products, H2 2017 49 Dormant Products, H2 2017 (Contd..1), H2 2017 50 Discontinued Products, H2 2017 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
